-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, CDE's official website showed that Jiangsu Hansoh Pharmaceutical's Vinorelbine tartrate soft capsules were accepted for production as a 4-type imitation, and it will be regarded as over-evaluation after approval
The data show that vinorelbine tartrate soft capsules can be used for patients with stage IIIB-IV non-small cell lung cancer with extrapulmonary metastasis who cannot tolerate intravenous administration
Sales of vinorelbine tartrate soft capsules in Chinese public medical institutions in recent years (unit: ten thousand yuan)
Source: Minet.
According to data from Minet.
Approval of Vinorelbine Tartrate Soft Capsules
Source: new version database of Minet
Only two companies, Pierre Fabre and Jiangsu Hengrui Medicine, have production approvals for Vinorelbine tartrate soft capsules, and no companies have been approved
Prior to this, Jiangsu Hansoh Pharmaceutical had 5 anti-tumor drugs under review under the new classification.
Source: CDE official website, Minet database